Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Living with Alzheimer’s disease can be both challenging and frightening. However, stories of resilience and hope can inspire ...

The eye test would be another tool for early diagnosis of degenerative brain diseases. A blood test that assists with early ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Alzheimer’s Association’s Bike to End ALZ cycling fundraiser across SC from Simpsonville to Charleston finished in Mount ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

We all forget things. Names, dates, phone chargers – even why we walked into the kitchen. It’s called being human… or, let’s be honest, being over 40 in a digital world with too many tabs open in our ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...